Repurposed drugs targeting multiple pathophysiological mechanisms may improve therapeutic outcomes in fibromyalgia.
This review discusses repurposed drugs for fibromyalgia, including NMDA receptor antagonists, neurokinin-1 receptor antagonists, GABA system drugs, antiepileptics, antidepressants, opioids, cannabinoids, dopamine receptor agonists, melatonin receptor agonists, and antidiabetics. It emphasizes a multi-target strategy addressing neurochemical alterations, central sensitization, neuroinflammation, oxidative stress, mitochondrial dysfunction, gut microbiota disturbances, and autoimmunity.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Repurposed drugs targeting multiple pathophysiological mechanisms may improve therapeutic outcomes in fibromyalgia. The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).
The Claim
Repurposed drugs targeting multiple pathophysiological mechanisms may improve therapeutic outcomes in fibromyalgia.
This conclusion is most relevant to: Fibromyalgia patients (general, with comorbidities).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Therapeutic and research frontiers in fibromyalgia: integrating pathophysiology with innovative drug repurposing. (Inflammopharmacology, 2026) —
How It Works
The proposed biological pathway:
- ▸Target neurochemical alterations and central sensitization
- ▸Enhance descending inhibitory pain pathways
- ▸Suppress neuroinflammation via NLRP3 inflammasome inhibition and anti-inflammatory glial polarization
- ▸Attenuate oxidative stress and mitochondrial dysfunction
- ▸Result: Improved therapeutic outcomes in fibromyalgia
Who Might Benefit
Evidence fit by population:
- ▸Fibromyalgia patients (general, with comorbidities)
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Many proposed mechanisms remain under investigation and are not yet well-established
- ▸The review does not provide quantitative effect sizes or specific clinical trial results for individual repurposed drugs
Frequently Asked Questions
What repurposed drugs are discussed for fibromyalgia?▼
The review discusses NMDA receptor antagonists, neurokinin-1 receptor antagonists, GABA system drugs, antiepileptics, antidepressants, opioids, cannabinoids, dopamine receptor agonists, melatonin receptor agonists, and antidiabetics.
What pathophysiological mechanisms are targeted?▼
Targeted mechanisms include neurochemical alterations, central sensitization, neuroinflammation, oxidative stress, mitochondrial dysfunction, gut microbiota disturbances, and autoimmunity.
Is this a clinical trial or a review?▼
This is a review article (not a clinical trial) that summarizes preclinical and clinical studies on repurposed drugs for fibromyalgia.
What future research frontiers are suggested?▼
Future research should focus on addressing comorbidities, enhancing descending inhibitory pain pathways, suppressing neuroinflammation via NLRP3 inflammasome inhibition, promoting anti-inflammatory glial polarization, and attenuating oxidative stress and mitochondrial dysfunction.
References
- 1.Joodi SA, Nawwar DA, Rasheed NOA, Ibrahim WW, Sayed HM. “Therapeutic and research frontiers in fibromyalgia: integrating pathophysiology with innovative drug repurposing..” Inflammopharmacology, 2026. PMID: 42489789 DOI: 10.1007/s10787-026-02349-5